-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Artery Network was informed for the first time that, recently, Hope Medicine Inc.
(Heqirui Medicine) (hereinafter referred to as "Heqirui") announced the completion of US$56 million in Series B financing.
This round of financing was jointly led by Qiming Venture Capital and Yuanyi Investment.
, Honghui Capital and Innovation Workshop followed up the investment, the old shareholder Trust Capital continued to support, Haoyue Capital acted as the exclusive financial advisor for this round of financing.
This round of investment will provide strong support for Herqirui's upcoming MRCT international phase II clinical research and product line construction.
Herqirui is a science-driven innovative drug research and development company dedicated to source innovation.
Focusing on the three major areas of women’s health, endocrinology and cardiovascular diseases, Heqirui has further established a diversified R&D pipeline through independent research and development and a license-in dual-drive model in response to the current unmet clinical needs.
Previously, Qirui and Bayer AG signed a global exclusive license agreement for the development and industrialization of monoclonal antibodies targeting the prolactin (PRL) receptor.
Professor Xiao Ruiping, founder, chairman of the board and CEO of Heqirui, said that we have a leading biomedical team, strong global intellectual property rights, and a determination to provide the best drugs to the global market.
Ms.
Mr.
Mr.
Mr.
Mr.
